We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Unique Patient Sample Transport Reagents Support Safer and More Reliable COVID Testing

By LabMedica International staff writers
Posted on 22 Sep 2021
A new range of products address a full spectrum of molecular and protein testing challenges made clear by the COVID-19 pandemic and the wildfire growth of the Delta variant.

Thomas Scientific (Swedesboro, NJ, USA) has partnered with Truckee Applied Genomics (TAG; Reno, NV, USA) to distribute its unique patient sample transport reagents. More...
Thomas Scientific has been appointed as the sole distributor for the US and Puerto Rico of TAG regents. The agreement provides an expanded distribution channel to research, diagnostic, and manufacturing customers, including clients in molecular pathology, diagnostic kit development, and variant tracking research labs.

With COVID-19 spread increasing from the Delta variant, demand for rapid antigen protein tests has surged and the need for broader NGS-based variant surveillance has become clear. As the diversity of testing has grown, it has become imperative that resources be designed to accommodate changing needs, while maintaining lab worker safety. One key factor for testing flexibility is enabling patient samples to be sent to any available lab without costly and error-prone cold chain shipping. Another key factor is designing in better safety from collection through lab processing, by inactivating virus before transport. With the growth of non-inactivating antigen tests kits, there is a clear need to develop new kits with reagents that inactivate virus to support safer handling.

Without virus inactivation, lab workers processing antigen tests face safety risks from viral exposure. While toxic guanidine-based virus-killing inactivating transport media (ITM) can preserve nucleic acids and be shipped without a cold chain, they do not work for antigen tests as they can denature proteins and interfere with rapid antigen testing mechanisms. And, for all test types, guanidine-based ITMs have safety and handling concerns as they produce toxic cyanide gas when used with bleach washing steps found in molecular testing processes and platforms.

TAG-NPGM+ and TAG-NGPM patient sample collection reagents contain no guanidine, providing better choices. TAG-NPGM+ rapidly inactivates the virus while preserving both antigen proteins and viral nucleic acids. This means that a patient sample collected in TAG-NGPM+ for an antigen test, could also be sent for a positive verification by a gold-standard rt-PCR test, and banked for NextGen Sequencing (NGS) enabling broader population variant tracking. Research Use Only (RUO) TAG-NGPM+ is a truly universal virus inactivating (safe) collection media that works end-to-end for antigen, rt-PCR and NGS tests, and enables lab staff to safely dispose of samples with common lab bleach.

“TAG is delighted to have Thomas Scientific distribute our products because of their deep technical understanding of the challenges of molecular diagnostics,” said Tian Yu, PhD MBA, VP Product Development at Truckee Applied Genomics. “Along with Thomas Scientific, TAG is meeting the need to improve pandemic preparedness, testing safety, and accuracy, while enabling better and broader variant tracking. And beyond TAG-NGPM+, we are glad to be partnering with Thomas Scientific, to find high-potential new applications for the company's non-crosslinking tissue stabilization reagent TAG-1 for oncology researchers, biotech companies, and innovative research labs to improve liquid biopsy, spatial genomics/transcriptomics, and biomarker development.”

"TAG's sample transport products bring an innovative new chemistry much needed by our molecular diagnostics customers. We see great potential for TAG products to improve the safety and test performance of our clients' labs," added Chad Jenkins, Vice President Thomas Scientific Peak Bio Solutions.

Related Links:

Thomas Scientific
Truckee Applied Genomics


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.